Results 201 to 210 of about 1,213,487 (359)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

, 2008
Tomasz Burzykowski, Marc Buyse, Martine Piccart, George W. Sledge, James Carmichael, Hans‐Joachim Lück, John R. Mackey, Jean‐Marc Nabholtz, Robert Paridaens, Laura Biganzoli, Jacek Jassem, M. Bontenbal, Jacques Bonneterre, Stephen Chan, Gül Başaran, Patrick Therasse   +15 more
openalex   +2 more sources

Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma [PDF]

, 2011
Whitney B. Pope, Albert Lai, Rupal I. Mehta, H. J. Kim, Joe X Qiao, Jonathan R. Young, Xi Xue, Jonathan Goldin, Matthew S. Brown, Phioanh L. Nghiemphu, Anh Tran, Timothy F. Cloughesy   +11 more
openalex   +1 more source

Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival [PDF]

Value in Health, 2013
Jeroen P. Jansen, Thomas A Trikalinos
openaire   +2 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility

South Asian Journal of Cancer
Santosh Kumar Swain, Lalatendu Moharana, Ghanashyam Biswas, Lipsita Samantaray, Ayush Dubey, Reetu Singhal, Bhavya Inimerla, Antara Sanyal, Swati Sucharita Mohanty, Soumya Surath Panda   +9 more
doaj   +1 more source

Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution. [PDF]

Am J Hematol
Dimopoulos MA, Ntanasis-Stathopoulos I, Fotiou D, Theodorakakou F, Solia E, Spiliopoulou V, Malandrakis P, Psimenou E, Giannouli S, Kanellias N, Koutoulidis V, Roussou M, Andrikopoulou A, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Terpos E, Kastritis E.   +17 more
europepmc   +1 more source

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712 [PDF]

, 2011
Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, R. Kanti, Richard A. Larson, John C. Byrd   +8 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point. [PDF]

BMC Med Res Methodol
Qiu Y, Li M.
europepmc   +1 more source